Adaptive stress signaling in targeted cancer therapy resistance

被引:40
|
作者
Pazarentzos, E. [1 ,2 ]
Bivona, T. G. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
关键词
CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; MEK INHIBITION; ANDROGEN RECEPTOR; BRAF(V600E) INHIBITION; FEEDBACK ACTIVATION; COLORECTAL-CANCER; NEGATIVE FEEDBACK;
D O I
10.1038/onc.2015.26
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize or eliminate targeted therapy resistance, thereby unleashing the full potential of targeted therapies to transform many cancers from lethal to chronic or curable conditions.
引用
收藏
页码:5599 / 5606
页数:8
相关论文
共 50 条
  • [11] Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment
    Luo, Zhihong
    Gong, Ke
    CANCER BIOLOGY & MEDICINE, 2024, 21 (10) : 831 - 837
  • [12] Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment
    Zhihong Luo
    Ke Gong
    Cancer Biology & Medicine, 2024, 21 (10) : 831 - 837
  • [13] mTOR Signaling Confers Resistance to Targeted Cancer Drugs
    Guri, Yakir
    Hall, Michael N.
    TRENDS IN CANCER, 2016, 2 (11): : 688 - 697
  • [14] Adaptive immune resistance in cancer therapy
    Jiang, Aimin
    Chen, Ouyang
    Liu, Zhigang
    Cai, Hongzhou
    Wang, Linhui
    Qi, Lin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [15] Overcoming Resistance to Targeted Therapy for Lung Cancer
    Govindan, Ramaswamy
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1760 - 1761
  • [16] Targeted therapy and drug resistance in thyroid cancer
    Zhang, Yujie
    Xing, Zhichao
    Liu, Tianyou
    Tang, Minghai
    Mi, Li
    Zhu, Jingqiang
    Wu, Wenshuang
    Wei, Tao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
  • [17] Advance in Targeted Cancer Therapy and Mechanisms of Resistance
    Tang, Patrick Ming-Kuen
    Zhang, Dongmei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [18] Role of Akt signaling in resistance to DNA-targeted therapy
    Avan, Abolfazl
    Narayan, Ravi
    Giovannetti, Elisa
    Peters, Godefridus J.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (05): : 352 - 369
  • [19] Uncovering adaptive mechanisms of resistance to targeted therapy in brain metastasis
    Adua, Sally J.
    Zhao, Minghui
    Smith, Paul
    Cross, Darren A.
    Nguyen, Don X.
    CANCER RESEARCH, 2019, 79 (13)
  • [20] The role of PTEN signaling perturbations in cancer and in targeted therapy
    Keniry, M.
    Parsons, R.
    ONCOGENE, 2008, 27 (41) : 5477 - 5485